10.5281/zenedo.15960797

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS

ISBN Number- 978-81-985724-7-9



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

Chapter- 4

BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN

MISS. KANASE SNEHA SAMPAT
Associate professor
Arihant College of Pharmacy, Ahilyanagar.
Pin code - 414005
Email: snehakanase.karad@gmail.com

PROF. SWAPNIL G KALE
Associate Professor
Arihant College of Pharmacy Ahilyanagar,
Pin 414005
Email: swapnilgkale01@gmail.com

GALGATE KANCHAN MOHAN
Associate Professor
Pin 414201
Email: pandulekanchan53@gmail.com

MS. MAHADIK MAYA RAKHMAJI
Assistant Professor
SAJVPM's College of Pharmaceutical
Science & Research Center Kada
Tal. Ashti Dist. Beed, Pin - 414202
Email: mayamahadik0@gmail.com

MR. CHOPANE ASHOK ANIL
Assistant Professor
Dharmaraj Shaikshanik Pratishthan's
College of Pharmacy,
Ahmednagar, Pin: 414005
Email: ashokchopane2018@gmail.com

10.5281/zenedo.15960797

Chapter 4….

BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN

MISS. KANASE SNEHA SAMPAT
Associate professor
Arihant College of Pharmacy, Ahilyanagar.
Pin code - 414005
Email: snehakanase.karad@gmail.com

PROF. SWAPNIL G KALE
Associate Professor
Arihant College of Pharmacy Ahilyanagar, Pin 414005
Email: swapnilgkale01@gmail.com

GALGATE KANCHAN MOHAN
Associate Professor
Pin 414201
Email: pandulekanchan53@gmail.com

MS. MAHADIK MAYA RAKHMAJI
Assistant Professor
SAJVPM's College of Pharmaceutical Science & Research Center Kada
Tal. Ashti Dist. Beed, Pin - 414202
Email: mayamahadik0@gmail.com

MR. CHOPANE ASHOK ANIL
Assistant Professor
Dharmaraj Shaikshanik Pratishthan's College of Pharmacy,
Ahmednagar, Pin: 414005
Email: ashokchopane2018@gmail.com

10.5281/zenedo.15960797

Through biopharmaceutics scientists evaluate the elements which influence drug release and absorption while determining its total bioavailability during pharmaceutical product development. Creating a compound which treats specific conditions is only half of drug formulation because it must also prioritize effective drug delivery to target areas. This section examines vital biopharmaceutic aspects involved in drug creation by examining factors that affect drug availability while describing delivery optimization difficulties.

The discussion starts by explaining the main elements that influence bioavailability because it defines both the extent and speed at which drugs enter the bloodstream to reach their intended sites of action. Knowledge about these determining factors enables both therapeutic outcome prediction and formulation development for maximum therapeutic benefit [1]. This section analyzes rate-limiting drug absorption steps that control both speed and efficiency of drug distribution to the target sites. The drugs dissolve process follows as the first step which is followed by permeability considerations before the drug encounters metabolic transformation.

This section analyzes drug formulation characteristics to investigate the effects of drug along with formulation physical and chemical properties on the absorption procedure. A detailed research explores both excipients and the drug's relationship with the dosage form as formulation-dependent elements. The last part of the chapter presents information about drug dissolution testing and different methods which can assess drug formulation performance. A drug’s ability to reach bloodstream depends on successfully meeting its dissolution specifications for proper and controlled delivery. The understanding of these concepts helps pharmaceutical scientists build better and more dependable drug delivery methodologies.

4.1 INTRODUCTION TO BIOPHARMACEUTICS

The scientific discipline of biopharmaceutics explores drug physical chemical properties combined with their dosage formats alongside ADME processes which represent absorption distribution metabolism and elimination suited to biological procedures of the body[2]. This scientific discipline plays an essential role because it establishes a connection between pharmacological principles and drug formulation development to reveal drug delivery pathways to intended targets.

10.5281/zenedo.15960797



Figure 1: Biopharmaceutics

A drug effectively works through both pharmacological characteristics and successful body processing of absorption distribution metabolism and excretion. This introduction explores primary determinants which affect drug availability and performance prior to developing efficient pharmaceutical formulations.

4.1.1 Bioavailability and Its Importance

The fundamental concept of pharmacology and pharmaceutical development exists in bioavailability definitions. Bioavailability represents the percentage of administered drug that successfully reaches mainstream circulation as an active form which produces its desired pharmacological outcome [3]. Scientifically speaking bioavailability defines the amount of drug that successfully passes through the bloodstream toward its activity site to generate therapeutic effects. Bioavailability holds special importance for oral medications since the body only absorbs a small portion of the administrated drugs whereas the rest gets destroyed during physiological processes including metabolism and absorption malfunctions.

- **Importance of Bioavailability in Drug Effectiveness**

The drug's ability to produce effects depends on the quantity of drug material which reaches the target site in the body at its therapeutic level. Bioavailability function as a main factor that decides this amount. The drug requires enough bloodstream concentration to properly activate its target receptors or tissues for effective therapy. The low bioavailability rate of a drug prevents therapeutic effects from developing in the bloodstream even when using high drug doses. Higher bioavailability leads drugs to reach systemic circulation effectively which enables them to work better with reduced dose requirements. The optimal therapeutic success

of a drug depends on comprehensive knowledge and optimization of metabolic delivery which establishes drug levels in bloodstream.

- **Factors Affecting Bioavailability**

The bioavailability of a drug depends on specific factors that begin with its physicochemical properties. Drugs absorbing well into gastrointestinal fluids have higher chances of passing through into bloodstream circulation[4]. The absorption of drugs through cell membrane lipid bilayers (lipophilic drugs) happens more easily. Bioavailability of the drug depends heavily on molecular size together with charge and polarity characteristics that aid in GI tract penetration leading to systemic circulation. The drug absorption ability heavily depends on the intestinal membrane permeability because drugs need to pass through this barrier to achieve effective absorption levels.

The bioavailability of drugs depends heavily on how the drug itself is formulated beyond its natural features. Both the pharmaceutical form of medication and inactive substance composition as well as release rate mechanism control how fast and how much medication gets absorbed by the body. The drug absorption rate increases when pills move from solid tablets to liquid form since more absorption surface area becomes available. Drugs reach their absorption targets differently because specific excipients modify the drug dissolution speed while impacting how the drug moves through the GI barrier.

- **Gastrointestinal Factors Impacting Bioavailability**

Through the gastrointestinal (GI) tract most drugs flow into bloodstream absorption channels. The features of a drug significantly determine the rate at which it enters the bloodstream. Drug absorption and solubility are influenced by the pH levels that vary between the acidic stomach region and the less acidic small intestine region of the gastrointestinal tract. Different drugs demonstrate optimal absorption rates under acidic solutions or neutral or alkaline environments.

Bioavailability of drugs depends on the transit time treatment duration in the GI tract. Prodrugs which spend short durations inside the stomach and intestines often fail to dissolve properly or absorb sufficiently. When a drug stays in the GI tract for an extended period it exposes more drug substance to initial liver metabolism which typically decreases the amount of drug reaching the bloodstream.

- **First-Pass Metabolism and Bioavailability**

A drug undergoes first-pass metabolism when it becomes metabolized inside the liver before traveling to systemic circulation. The drug crosses from the GI tract into the portal blood after absorption before reaching the liver for first-pass metabolism. The extensive first-pass metabolism converts drugs into inactive metabolites that reduce the available concentration of active drug substance reaching the body. There are specific drugs which need alternative administration routes like intravenous and sublingual routes to bypass first-pass metabolism because oral drugs particularly benefit from higher bioavailability levels.

- **Bioavailability in Drug Development**

Drug development requires examination of bioavailability because it directly affects the safety and efficacy levels of drugs. The study of bioavailability influence factors allows pharmaceutical scientists to optimize drug formulations along with designing delivery systems which maximize drug absorption and decrease drug waste. Scientists enhance drug performance by making chemical changes or employing liposomes or nanoparticles together with adjusting dosage forms to optimize drug release characteristics. Balancing bioavailability at its optimal level enables drugs to reach target areas with correct concentrations over specified periods which enhances therapy effectiveness.

4.1.2 Factors Affecting Bioavailability

The quantity of administered drugs that moves from its administration site to the bloodstream before therapeutic action depends on bioavailability [5]. The bioavailability journey of drugs changes following multiple factors because it represents the evolving process that starts with drug administration then leads to therapeutic action. Bioavailability depends heavily on four fundamental elements such as drug physicochemical properties and dosage form and formulation as well as gastrointestinal physiology and metabolism. The lifefor road to drug bioavailability is conditional upon every separate factor because these elements respectively contribute to maintaining proper drug absorption and circulation to target locations at effective levels.

- **Physicochemical Properties of the Drug**

Drug properties that exist within the substance serve as critical factors which determine how a medicine absorbs into the body and becomes available for therapeutic use. The properties influence how well drugs can pass through membranes while reaching systemic circulation. The primary physicochemical properties consist of the following points:

- **Solubility:** The drug requires solubility within gastrointestinal fluids in order to absorb it through dissolution. The absorption levels of drugs which have low solubility rates typically remain below average since it becomes difficult for these medications to dissolve in the body. The drug's molecular structure together with its bond behavior within the aqueous gastrointestinal fluids establishes solubility.
- **Molecular Size:** Smaller molecules demonstrate better membrane permeability than larger molecules do when passing through cell walls. Big molecules need endocytosis as well as additional mechanisms for successful permeation across the gastrointestinal epithelium.
- **Charge:** The state of drug ionization at gastrointestinal tract physiological pH determines how well the drug absorbs. The permeability rate of lipids in cellular membranes differs between ionized drugs and non-ionized drugs. The pH of the environment controls drug ionization due to its importance in drug absorption based on the pH-partition theory.
- **Lipophilicity (Fat-Solubility):** Drugs that show affinity for fat chemicals tend to cross through the lipid membranes that protect the gastrointestinal tract. Fast absorption happens with lipophilic drugs yet they need special formulation methods since they lack proper water-based gastrointestinal solubility.

➢ **Dosage Form and Formulation**

Bioavailability of drugs heavily depends on their formulation routine. The drug industry develops multiple drug formulations consisting of tablets and capsules together with solutions and suspensions and injections. Drug formulation controls both the rate of drug release from its billing and the absorption efficiency through the gastrointestinal system.

- **Solid Dosage Forms (e.g., Tablets and Capsules):** The drug needs to dissolve into solution prior to absorption processes. The dissolution rate depends on three main factors which include drug chemical form together with excipients used for formulation such as binders and fillers and the physical structure of the dosage form. Drug formulations for solid dosage forms cause drugs to dissolve at varying speeds which affects both absorption onset and drug uptake.
- **Liquids:** The rapid absorption of drugs occurs through liquid forms because solutions and suspensions do not require dissolution before absorption. The stability issues alongside accuracy problems persist as main challenges for liquid drug formulations.

- **Modified-Release Formulations:** Pharmaceutical companies create drugs which provide gradual time-dependent medication release through extended-release or controlled-release methods. Through these particular formulations drug release occurs gradually which sustains therapy effects and reduces changes in drug concentrations. Directed release system design needs to combine two key requirements for drugs: proper drug delivery control and extended therapeutic availability.

➢ **Gastrointestinal Environment**

The drug dissolution process along with absorption gets strongly impacted by how the gastrointestinal (GI) tract's environment functions. The features of the GI tract have dual roles in drug absorption because they can either accelerate or slow down drug absorption processes.

- **pH:** A pH gradient spans the gastrointestinal duct since its stomach area maintains acidity while its small intestinal segment stays neutral. The solubility together with ionization of numerous drugs derives from pH yet this process influences drug absorption. An acidic drug environment enhances their absorption from the stomach yet basic drugs benefit most from absorption within the alkaline small intestine.
- **Gastric Emptying Time:** Drug stay time in the stomach depends on the speed at which stomach contents move into the small intestine. The movement speed of stomach contents through gastric emptying determines how soon the small intestine can absorb the drug substance. Drug absorption timing and extent both suffer when patients eat fatty foods that delay the movement of stomach contents during digestion.
- **Presence of Food or Other Drugs:** Several factors affect the drug absorption process when food is present in the body. Drugs interact with food by slowing down stomach emptying while changing stomach acidity levels and directly impacting drug absorption which may lead to either better or worse drug absorption rates. Several drugs that are consumed simultaneously produce interaction effects that modify their absorption process. The gastrointestinal environment faces modification from certain drugs that modify stomach pH levels and enzyme actions or block the available transporters which impacts drug absorption rates.

➢ **Metabolism and First-Pass Effect**

A drug undergoes liver-based metabolism during the first-pass effect prior to reaching systemic circulation. Bioavailability for orally taken drugs significantly depends on this critical factor.

10.5281/zenedo.15960797

- **Liver Metabolism:** Absorbed drugs enter the portal circulatory system before immediately being routed to the liver. The drug passes through enzymatic processes in the liver which mainly occurs through the cytochrome P450 enzyme system. The biochemical transformation within the body results in substantial drug reduction that minimizes its available concentration as an active compound in systemic circulation.
- **First-Pass Effect:** Drugs initially metabolized during the first-pass experience significant removal of their active compounds which decreases their availability in the body. The effect of first-pass metabolism requires patients to take higher oral doses of medications which possess substantial first-pass metabolism. Drugs subject to minimal first-pass metabolism preserve a high level of their bioactivity when taken orally.

4.1.3 Role of Drug Formulation in Bioavailability

Drug formulation determines how much and how fast drug molecules will pass across into bloodstream as bioavailability thus affects the availability of active ingredients. Drug formulation controls both drug absorption at the administration site along with transport to the targeted tissue and organs [6]. The formulation shapes drug delivery because it controls important pharmacokinetic elements which include solubility and dissolution rate together with release mechanisms that decide the amount of medication which reaches blood circulation.

The delivery and absorption of drugs in the body depend considerably on which form the medication takes between solids and liquids or extended-release preparations. A drug designed as a solid substance such as tablets or capsules needs to dissolve first within the gastrointestinal tract before the body absorbs it through blood circulation. A drug which fails to dissolve quickly from its formulation will lead to reduced bioavailability. Faster drug absorption through liquid formulations such as solutions or suspensions is possible because these solutions have already reached a dissolved state yet their overall bioavailability remains subject to gastric emptying rates and GI tract drug interactions.

The purpose of sustained-release medication and controlled-release formulations is to provide methodical drug release throughout a lengthened duration. The controlled drug release systems enable better bioavailability by generating consistent blood drug levels which reduces the severe peaks and valleys that immediate-release drugs would produce. The drug produces advantages through its controlled distribution method which maintains therapeutic outcomes while lessening side effects due to extreme concentration levels. Sustained-release formulations help patients require fewer doses which increases their medicine compliance rate and potentially decreases the occurrence of adverse reactions. The design process needs

attention to detail because it affects how the drug releases in accordance with the body's absorption abilities throughout the period.

The bioavailability depends significantly on formulation choice together with excipient selection for non-active formulation ingredients. Drugs containing excipients such as binders and fillers and lubricants and disintegrants will modify the solubility and dissolution rate and permeability of active ingredients. Some excipients specifically help improve the solubility of drugs having low solubility rates to maximize bioavailability. Drugs absorb sub optimally when excipients that were selected wrongly lower drug stability and decrease drug solubility. According to pharmaceutical design principles excipients need proper development because this determines how a drug reaches the bloodstream successfully.

4.1.4 The Role of Biopharmaceutics in Drug Design

New drug development strongly relies on biopharmaceutics because this discipline delivers comprehensive information about drug behavior inside the human body. Biopharmaceutics fills the void between drug chemistry and physiology by determining proper drug concentration and delivery to its target site that produces therapeutic results. The development of effective and safe patient drugs requires this fundamental knowledge for design purposes.

Drug design projects rely on biopharmaceutics to forecast all aspects relating to drug absorption, distribution, metabolism and elimination (ADME). Medical experts evaluate four essential processes which explain drug absorption into bloodstream circulation along with body diffusion patterns and metabolic breakdown in the liver before explaining methods of drug elimination by the body. Scientists use biopharmaceutics to discover the bioavailability amount of the administered dose that reaches bloodstream as an active compound thanks to understanding these pharmacological processes.

During the absorption phase a drug travels from where it was administered which typically happens in the gastrointestinal tract to reach the bloodstream. Biopharmaceutics investigates the elements that shape drug absorption via evaluation of drug dissolution rates together with membrane permeability and gastrointestinal survivability factors. Scientists use this knowledge to pick the best drug form and excipients that increase drug absorption allowing them to choose sustained-release products or improve solubility-enhancing materials.

The body-wide drug spread plays a vital role in determining the drug's overall functioning. The field of biopharmaceutics reveals essential drug behaviors when drugs affect bodily tissues and bind to blood proteins. Drugs undergo distribution studies to develop medications which

specifically direct their treatment effects to particular areas of the body through targeted drug delivery and biologic therapies focused on disease sites. The creation of monoclonal antibodies displays specific cell targeting capacity which reduces their harmful effects on normal body tissues.

Drugs require consideration of metabolism patterns as a vital aspect for their design. Many therapeutic compounds transform through metabolic processes that mostly happen inside the liver and this process results in either activated drug components or inactive products. Through Biopharmaceutics researchers obtain drug metabolism forecasting abilities which leads them to discover metabolic products and their associated safety risks both during drug interactions and following metabolization. The first-pass effect is essential since drugs undergo physiologic alterations that occur in the liver thus decreasing the drug's availability in systemic circulation. The design of pharmacologically advantageous drugs and improved drug delivery strategies together with first-pass metabolism reduction are possible through biopharmaceutics applications.

The method by which a drug leaves the body stands as an essential element among pharmacokinetic variables together. Drugs leave the body through two known routes: they exit through urine through the kidneys while the liver removes them as bile. Research teams use drug clearance data to establish appropriate dosing plans which deliver the correct therapeutic concentrations without causing drug accumulation or harmful effects.

Biopharmaceutics performs an essential function during formulation development in addition to its ADME prediction tasks. Researchers use knowledge of body-based drug barriers to develop medications which successfully bypass such obstacles. Drug formulation with excipients that enhance dissolution rates and delivery through nanoparticles represents advanced delivery systems that boost bioavailability.

4.2 RATE-LIMITING STEPS IN DRUG ABSORPTION

Drug absorption consists of several complex processes which requires detailed knowledge about rate-limiting steps because this knowledge leads to optimized drug formulations as well as enhanced bioavailability. Drug absorption completes through rate-limiting steps that function as slowing factors which determine both speed and efficiency of bloodstream entry for drugs [7]. Drug absorption goes through various steps which become affected by different factors such as drug physical properties and pharmaceutical design and GIT characteristics. The drug absorption process depends on dissolution and permeability and transport

10.5281/zenedo.15960797

mechanisms as three main rate-limiting steps which determine the drug's successful transfer into systemic circulation.

4.2.1 Dissolution Rate as a Rate-Limiting Step

The process of drug absorption starts with dissolution which represents one of the key elements that determines how well a drug enters the systemic circulation. The gastrointestinal (GI) membrane refrains any drug from entering bloodstream until the drug dissolves within GIT fluids including gastric juices and bile. The enterocytes can only absorb drugs which have become dissolved so this step presents essential requirements. The therapeutic outcomes of any drug depend directly on its dissolution rate because it determines both drug availability and effectiveness.

The drug dissolution process develops into a crucial rate-limiting step when medications have low solubility because it generates prolonged inefficient drug dissolution times. The reduced availability of drugs for absorption creates lower drug effectiveness because of poor dissolution behavior. The bioavailability of poor solubility drugs suffers because the undissolved drug stays in GI tract tissues instead of crossing through the intestinal epithelium. Drugs with slow dissolution rates produce less available drug substance for body therapeutic action.

Several elements determine drug dissolution rates in the body by controlling the physical state of the drug substance as well as its ability to dissolve within stomach and intestinal fluids and the acidity of those fluids. Drug dissolution speed depends notably on the actual physical state of the drug between tablets or capsules or liquid formulations. The dissolution time of tablets and capsules tends to exceed that of liquid formulations and suspensions since suspensions already contain drug particles as dissolved units. Solid pharmaceutical products need extra measures for dissolution enhancement because of their delayed absorption potential.

- **Solubility and the Role of pH**

The dissolution rate depends heavily on solubility as an important influencing factor. The absorption rate becomes delayed when drugs having low water solubility struggle to dissolve properly in GI fluids.



Figure 2: pH and Solubility

Multiple substance characteristics determine the solubility of drugs through their molecular dimensions together with their polarity characteristics alongside their crystal lattice pattern. Drugs with hydrophobic properties present difficulties for dissolution because they resist dissolving efficiently in aqueous fluids which occupy the gastric and intestinal region.

Dissolution of medication depends heavily on the pH conditions found throughout the gastrointestinal system. The stomach maintains an acidic environment with between 1.5 to 3.5 pH compared to the small intestine which has a more alkaline condition reaching pH 6 to 7.5. A drug tends to dissolve better at specific pH levels because its solubility depends on environmental pH in the GI tract. Drugs with weak acid-base properties reach maximum solubility either in stomach fluids or intestinal fluids based on their pKa value measurement. The drug absorption rate becomes directly influenced by the dissolution rate which changes because of local pH conditions throughout the GI tract.

- **Formulation Strategies to Overcome Poor Dissolution**

Formulation scientists use different approaches to enhance both the dissolution rate and bioavailability of drugs which have limited solubility properties. The surface area of the drug needs enhancement as a strategy for improvement. When drug particles become micronized or nanonized their surface area increases substantially for dissolution purposes. The dissolution process happens swiftly when drugs have diminutive particle sizes which results in faster drug effects.

The administration of solubilizing agents known as cyclodextrins represents a valuable method to improve drug dissolution rates. The cyclic nature of oligosaccharides in cyclodextrins allows them to create inclusion complexes with medications that show poor solubility which enhances dissolution in water-based solutions. Drugs become more absorbable because the complexes establish better dissolution properties in aqueous solutions. Surfactants together with other excipients help enhance solubility by modifying drug properties and through reductions in surface tension.

The absorption requirements of specific drugs often drive healthcare providers to select immediate-release formulations because of their quick dissolution properties. The designed pharmaceutical formulations enable rapid breakdown within the stomach space to immediately convert drugs into solution without involving time-consuming dissolution processes. Fast-dissolving pharmacological formulations built with effervescent or rapidly disintegrating tablets serve drugs needing rapid dissolution or providing instant therapeutic results including pain medications and antacid medications.

➢ **Sustained-Release Formulations and their Impact on Dissolution**

A different approach to improve drug dissolution involves creating sustained-release or controlled-release delivery systems. This formulation type does not solve immediate dissolution issues but it controls drug release rates to achieve longer drug presence in the GI tract. Solutions with controlled drug release provide benefits to poorly soluble medicines because the consistent release rates improve their bioavailability by easing dissolution and absorption throughout the absorption period. The controlled-release formulation works best on drugs that need precise monitoring of therapeutic thresholds and quickly detach from the body.

4.2.2 Permeability as a Rate-Limiting Step

A drug needs to penetrate GI epithelial cells before they can reach bloodstream circulation after GI fluids dissolve the medication. The drug needs to pass biological membranes as this stage forms a critical part of the absorption process to access systemic circulation. Lengthy medication absorption through epithelial GI tract barriers determines the efficiency of drug absorption. The absorption rate of drugs with low permeability may be limited by this step which creates poor bioavailability because the drug does not reach systemic circulation properly.

➢ **Factors Affecting Permeability**

The permeability of drugs across intestinal cell membranes gets influenced by multiple strategic factors. Drugs reaching intestinal membrane permeability mainly depend on their size and fat-solubility along with their molecular charge.

1. **Size**: Cell membranes enable smaller molecules to penetrate their barriers with greater case than larger molecules. Smaller drugs escape through the lipid bilayer membranes efficiently because diffusion functions better for these molecules compared to how larger molecules require specific transport mechanisms.
2. **Lipophilicity**: Lipophilic drugs recognize cellular membranes as a suitable conduit because their passage through fat-based structures occurs more easily than hydrophilic drugs. The cell membrane consists mainly of a lipid bilayer which lipophilic drugs dissolve easily in its lipid environment before moving through passively by diffusion. Hydrophilic drugs encounter major execution barriers because the lipid bilayer persists refractory to their dissolution. Some drugs need membrane-crossing mechanisms which include carrier proteins together with specific transporters for passage through the membrane.

3. **Molecular Charge**: A drug molecule requires an appropriate electrical charge to properly permeate through a cell membrane. The neutral state of molecules makes them prefer passive diffusion across the membrane because charged molecules tend to resist the hydrophobic nature of lipids. Weak acids and bases alongside many other drugs transform their structure according to the pH level of their surrounding environment. Drug permeability across intestinal epithelium depends greatly on drug ionization status since positively and negatively charged forms are less permeable than uncharged versions.

- **Efflux Pumps and Active Transport**

Drug permeability can be modified by activity of intestinal epithelial cell efflux pumps. Efflux pumps serve as membrane proteins which transport drugs together with other substances from cells through the gastrointestinal tract lumen. The body maintains these defense system pumps as natural components which release drugs through the intestine before they enter bloodstream circulation. P-glycoprotein (P-gp) efflux pump functions as a common defense mechanism that reduces drug absorption by transporting substances out of enterocytes (intestinal cells). These transport pumps demonstrate substantial influence on drug therapeutic effects because their activity decreases the availability of drugs that efflux transporters recognize as their substrates.

A small group of drugs requires the mechanisms of facilitated and active transport for efficient absorption to occur. Substances that undergo active transport need carrier proteins along with energy sources to cross membranes against their concentration gradient. The active transport process provides great value for pharmaceutical substances which have similar structures to essential endogenous compounds such as glucose along with amino acids and peptides. Drugs may fail to absorb through this process once transporters reach saturation levels or when inhibitors block the transporter function.

- **Overcoming Permeability Barriers**

Different methods exist to improve permeability of difficult-to-absorb drugs in order to enhance their absorption rates and bioavailability levels. Drugs require absorption enhancers as an approach for improved absorption. The addition of excipients to the drug allows them to create momentary disruptions that increase the permeability of intestinal cell membranes. The intestinal epithelium barrier function can be weakened by surfactants together with certain bile salts which results in improved drug absorption throughout the intestinal tract.

Nanoparticles along with liposomes represent another method for delivering drugs. Drugs placed inside these delivery systems maintain protection from efflux pumps and undergo controlled timed releases of medication. The use of engineered nanoparticles leads to three main improvements: better drug stability with increased solubility and drug permeability capabilities. The utilization of nanoparticles which reduce drug dimensions or expand their surface exposure or alter their surface energetic properties leads to better drug passage through cellular membranes via passive diffusion.

The spherical lipid-composed Liposomes serve as drug carriers by forming membrane bilayers which help drugs cross intestinal epithelium more effectively. The bioavailability of drugs with low permeability becomes better through cuplike liposomal structures specifically when drugs have poor solubility or display sensitivity to efflux pump activity.

4.2.3 Transport Mechanisms as Rate-Limiting Steps

Drugs absorb through the body primarily through transport mechanisms which function as important factors during oral drug administration. The GIT functions as both a drug dispersion location and a permeability barrier which multiple transport pathways manage how drugs transit across the epithelial tissue into the bloodstream. These drug transportation pathways act as limiting factors if they work improperly or reach their capacity point because they reduce drug absorption rates and affect drug concentration in the blood.

- **Passive Diffusion and Its Limitations**

The majority of drugs passes through the body by passive diffusion mechanisms. The drug molecules transfer naturally from areas with high concentration levels in the gastrointestinal lumen toward lower concentration areas in epithelial cells and bloodstream. The lipid bilayer of intestinal mucosa allows small non-polar lipophilic molecules to easily pass through it without needing energy investment.

Meetings between passive diffusion and absorption limitations reduce its efficiency. The diffusion process prevents large molecular compounds and highly polar substances as well as drugs that have minimal lipid solubility from passing through cell membranes. The diffusion speed depends directly on these three factors involving concentration gradient along with membrane surface area and membrane thickness. A drug absorption process through passive diffusion becomes inefficient when the drug fails to achieve therapeutic plasma values during its brief time in the GIT. Formulation avoidance of rate-limiting passive diffusion may require

modifications to chemical compounds or the addition of absorption enhancers because the mechanism slows the delivery of drugs.

- **Active Transport and Its Role in Specific Drug Absorption**

The energy-dependent transport mechanism operates by active transport to move drugs beyond their normal concentration gradient. Specialized transmembrane carriers perform drug-related transport operations through their role as efflux and influx transporters enabling drug uptake or release across membranes. Drugs that bear resemblance to glucose and amino acids along with nucleosides require active transport for absorption across cellular barriers. Similar drug structures enable drugs to exploit established nutrient transport systems through which they pass through intestinal tissues.

The drug absorption capabilities of active transport increase at low drug concentrations but the system imposes specific performance constraints. The drug absorption reaches its limit when all transport protein binding sites become occupied because these proteins demonstrate a restricted capacity for binding. Even when introducing additional drug amount to the system the bioavailability reaches its maximum threshold thus active transport becomes a possible performance bottleneck.

The absorption efficiency of a drug gets reduced when multiple substrates strive to use the same transporter system. Both drugs that share a single transporter system will block their mutual absorption during transportation across cellular barriers. Drug absorption together with therapeutic efficacy reduces when specific drugs or dietary components block active transport function.

- **Efflux Transporters and Their Impact on Drug Absorption**

Following epithelial cell entry, the intestinal drug compounds are repumped outside the body by the active transporters P-gp, MRPs and BCRP through the intestinal lumen. These protective proteins defend the body against substances that could prove harmful but simultaneously create substantial challenges for oral drug absorption. Drugs serving as substrates for these efflux proteins face reduced bioavailability because they continuously come under transport from intestinal cell linings to the intestinal lumen where they should not enter the bloodstream.

When drug absorption occurs this way, transport out of the cell becomes the primary factor that slows down delivery rates. Researchers in formulation science develop two approaches to beat efflux transporters by administering co-administered efflux blocking substances or through drug delivery solutions including nanoparticles and liposomes.

4.2.4 Gastric Emptying and Transit Time

The critical physiological processes of gastric emptying together with gastrointestinal transit time heavily affect drug absorption and therapeutic effectiveness because they determine the availability and absorption site. The time drugs stay in various sections of the GI tract is controlled by these processes while they determine both the absorption amount and location of the active pharmaceutical ingredient.

- **Role of Gastric Emptying in Drug Absorption**

During gastric emptying the gastrointestinal tract releases stomach contents into the small intestine. Applications of drugs depend heavily on the several systemic factors that affect gastric emptying because of meal characteristics and formulation and metabolic state.

When fasted the stomach releases food residues at a steady rate by using migrating motor complex (MMC) motor activities to clear any leftover ingesta after eating. The digestive process under fed conditions decreases gastric emptying thereby extending time needed for digestion so the drug reaches the small intestine where absorption occurs mainly due to the large surface area and extensive blood supply [8].

Drugs that absorb mainly in the small intestine experience delayed absorption when treated by slow gastric emptying which typically occurs after consuming fatty foods. The delayed drug arrival controls maximum plasma concentration levels (Cmax) and extends maximum plasma time (Tmax) thus influencing its effect onset. Delayed gastric emptying supports drugs that are sensitive to acidic conditions and drugs that generate local irritations because it helps shield drugs from destructive degradation when placed within acidic environments.

- **Small Intestinal Transit Time and Its Significance**

The absorption window of drugs in the small intestine depends heavily on the length of time the drug spends in this region after entry. The transit duration within the small intestine proves steadier than gastric emptying since most people need about 3 to 4 hours for completion. Drugs reach the small intestine as a relatively constant environment for absorption to occur. A drug that requires time to dissolve may fail to be absorbed adequately through the intestinal wall because the absorption window proves too short when permeation occurs slower than intestinal transport.

Drugs can benefit from intestinal stability to produce short-acting and long-acting oral pharmaceuticals that developers create as formulation experts. The drug concentration in the

intestine lengthens by using extended-release formulations which simultaneously advances drug absorption times and minimizes daily medication intake.

➢ **Colon Transit Time and Sustained Release**

Drugs developed for sustained release distribution eventually reach the colon because the longer transit time enables absorption of the compounds through the colon's tissues. The process of colonic transit lasts for 12–24 hours or longer yet presents various hurdles related to diminished size and reduced liquid content together with dense epithelial cells that reduce passive diffusion capabilities. Drug bioavailability might get impacted by chemical stability modifications and metabolic processes which happen due to colonic microflora presence along with elevated pH levels.

The limitations of the colon do not preclude its use for drug absorption because specific drugs will show stability and solubility within colonic environments. The creation of delivery systems intended for the colon has developed because of requirements to target drugs administered for inflammatory bowel disease treatment and systemic conditions requiring continuous plasma drug concentrations.

➢ **Formulation Strategies to Modulate Transit**

To mitigate the impact of variable gastric emptying and optimize absorption, pharmaceutical scientists employ several formulation strategies. These include:

- **Use of excipients** The drugs exhibit two mechanisms that independently adjust GI motility by controlling gastric emptying rate and intestinal transit speed.
- **Designing matrix-based or coated formulations** The drug delivery system consists of materials which avoid disintegration in the stomach while delivering medication over time in the small intestine or colon.
- **pH-sensitive systems** that dissolve only at specific pH levels encountered in different parts of the GI tract.
- **Osmotic pump systems** that allow for a controlled and steady release of drug independent of GI motility or food intake.

The utilization of such administrative strategies stretches therapeutic drug levels within the approved window thus improving both treatment effect and patient adherence through reduced medication frequency.

10.5281/zenedo.15960797

4.2.5 First-Pass Metabolism

Drug absorption experiences an important rate-limiting effect through first-pass metabolism which occurs in the liver. When drugs reach the gastrointestinal tract they enter the blood before proceeding to the liver on their way to systemic circulation. The liver handles numerous drugs during metabolism which leads to decreased availability of these medications in the body. A large number of drugs that undergo extensive first-pass metabolism experience reduced blood concentrations that significantly affect their therapeutic value.



Figure 3: First-Pass Metabolism

Some treatments employ sublingual tablets and transdermal patches because these bypass first-pass metabolism to help drugs calculate systemic circulation without liver exposure. The use of enzyme inhibitors constitutes an approach for reducing metabolic breakdown of drugs so that patients get higher drug availability.

4.3 PHYSICOCHEMICAL NATURE OF DRUG FORMULATIONS

Drug formulation properties directly impact drug characteristics that affect its delivery into the body as well as its availability and therapeutic impact [9]. Various therapeutic characteristics which form a group of properties include solubility and particle size along with polymorphism and pKa and lipophilicity and stability. Pharmaceutical scientists utilize their knowledge to control parameters which enable them to create formulations that enhance drug delivery to human tissues.

4.3.1 Solubility and Dissolution Rate

The solubility parameter stands as an essential physical characteristic for drug development because it regulates the amount of available drug substance which dissolves for absorption. A drug's therapeutic action requires its dissolution within GI fluids until permeating the GI mucosal lining for systemic circulation. Drugs with low aqueous solubility characteristics face significant obstacles to reach desired plasma concentrations which subsequently leads to unpredictable drug responses.

Both dissolution rate and speed at which drugs dissolve in solvents matter equally because they determine how fast drugs become available for absorption. The dissolution process decreases due to slow dissolution rates regardless of the drug's natural solubility capacity. Throughout the course of treating patients through oral medications that come in tablets and capsules form these drugs need to dissolve properly in GI fluids to become ready for absorption.

A wide range of methods developed by pharmaceutical scientists improve both the drug's solubility level and its dissolution speed. Among all drug enhancement strategies particle size reduction stands as the most frequently utilized technique. Drug particle size reduction through micronization or nanonization results in dramatic growth of available dissolution surfaces. The Noyes-Whitney equation shows that dissolution rates of solids have a direct relationship with surface area. The enhanced dissolution rate of smaller drug particles leads to better drug absorption chances through increased drug absorption efficiency [10].

The formation of salt derivatives stands as one of the principal methods to utilize in pharmaceutical products. The transformation of drugs which behave as weak acids or bases into water-soluble forms can be achieved by adding suitable counterions during reactions. Certain salt forms of weak acids and weak bases as sodium salts or hydrochlorides show better dissolution capabilities within gastric and intestinal fluids thus increasing their absorption rates.

Formulation design benefits strongly from surfactant introduction as an effective technique. The presence of surfactants in drug solutions decreases the force binding the drug to the medium so wettability and dispersion conditions improve. The drug solubilization process becomes more efficient because lipophilic drugs dissolve better through this approach while their dissolution rate improves as well. Solid dispersions of drugs dispersed in hydrophilic polymers create amorphous and molecularly dispersed states that enhance dissolution rates compared to crystalline forms of drugs.

The goal to enhance drug solubility within biological fluids and boost bioavailability can be achieved through complexation with cyclodextrins and the use of self-emulsifying drug delivery systems (SEDDS) and lipid-based formulations.

4.3.2 Particle Size and Surface Area

The drug's dissolution rate depends heavily on particle size because such physical parameter determines oral bioavailability for drugs that exhibit poor water solubility. The fundamental rate of dissolution links directly to the surface area which the solute particles expose. Smaller particles create additional drug contact surface with GI fluids which results in faster dissolution and enhanced absorption.

The field of present-day formulation technologies uses this principle chiefly for creating nanoparticles and microparticles. The creation of nanoparticulate systems significantly boosts the absorption rates of Biopharmaceutics Classification System (BCS) Class II drugs since this category contains compounds that have high permeability but weak solubility. The development of fenofibrate and itraconazole in nanosized drug particle form resulted in substantial improvements in their bioavailability levels. Rapid dissolution occurs within the upper GI tract due to the smaller size of these particles which results in improved absorption rates.

The particle reduction process comes with formulation complexities even though it offers various technical benefits. Drugs with ultra-fine particle sizes show high surface energy that promotes aggregation behavior under conditions of elevated moisture and production stages. The positive effects from size reduction might be eliminated because aggregation reduces available surface area. Poor flowability is another side effect of very small particles since they become challenging to process during both compression when making tablets and filling capsules [11].

Formulators combat these problems through addition of excipients such as surfactants together with polymers and stabilizers. Such additives help sustain particle dispersion through their ability to decrease surface tension while stopping agglomeration between particles. Several additives exist to stabilize nanocrystals and microparticles such as poloxamers and polyvinylpyrrolidone (PVP) and sodium lauryl sulfate (SLS). Spray drying together with wet milling and high-pressure homogenization serve as advanced techniques for the production of stable particles with uniform size distribution.

The reduction of particle size has substantial impacts on formulation properties because it affects taste, makes materials more moisture sensitive and leads to batch-to-batch dissolution variability. It is vital to measure particle size rigorously by employing laser diffraction or dynamic light scattering or microscopy throughout formulation development.

4.3.3 Polymorphism and Crystalline Form

A material exhibits polymorphism when it shows multiple crystalline forms especially in drug compounds. The different crystal patterns that exist for one chemical compound are known as polymorphs although all these forms share the same chemical identity. The diverse crystal arrangements generate substantial variations between internal material characteristics including melting point, solubility, density, hardness, hygroscopicity and critical properties of dissolution rate and bioavailability [12].

Medical science studies polymorphism as an essential factor because drug dissolution speed and quantity directly depend on drug crystal structure. The energy state of a drug crystal determines its thermodynamic stability where more stable forms dissolve slower whereas metastable forms along with those with disordered structures dissolve at higher rates. Drugs with amorphous structures cannot form crystal lattices so they experience swift dissolution in gastrointestinal fluids because they do not need to overcome any binding energies. Better drug solubility leads to superior bioavailability particularly when the drug displays limited water solubility. The quick dissolution benefits of metastable and amorphous forms do not extend into long-term stability. Such drugs have a tendency to transform into their more stable crystalline state when exposed to conditions like humidity and temperature changes as well as storage time which could degrade their drug performance. A complete preformulation investigation becomes essential because it helps determine the stability status of selected pharmaceutical forms until the prescribed drug expiry date [13].

All polymorphs in drug substances need complete regulatory characterization and standard manufacturing processes. A polymorph change impacts drug bioavailability and could result in therapeutic problems including failure of the treatment. The FDA along with EMA demand complete records on polymorphic profiles which incorporate either X-ray powder diffraction differential scanning calorimetry or infrared spectroscopy techniques to identify each form while providing evidence for selection criteria and production influence and shelf life properties. Identifying all crystalline drug substance forms becomes essential for pharmaceutical scientists through polymorph screening during medication development initial phases [14]. The most beneficial crystalline form selection takes place when manufacturers

equally consider the elements of solubility and stability with manufacturability and regulatory standards. The development of formulation strategies requires either stabilizing the drug substance in solid dispersion form or selecting crystalline structures that maintain drug stability and therapeutic performance.

4.3.4 Lipophilicity and Partition Coefficient

A drug's affinity towards lipid environments manifests as partition coefficient (log P) which compares the substance between water and octanol. Drugs need this property to pass through biological membranes especially when they have to penetrate the lipid-rich cell membranes from the intestinal epithelium.

The optimal drug lipophilicity exists between hydrophilic and lipophilic characteristics since drugs with a high hydrophilicity penetrate membranes poorly while extremely lipophilic drugs dissolve poorly in aqueous solutions. The log P value of an ideal candidate drug should fall between 1 and 3 to achieve proper solubility together with membrane permeability [15].

4.3.5 Ionization and pKa

Drug ionization patterns determined by pKa and solution pH values influence drug solubility in addition to drug membrane permeability. A drug needs to exist as its unionized form for the pH-partition theory to allow its membrane crossing ability. The pKa value of a drug allows healthcare professionals to forecast which part of the GI tract will offer the best absorption conditions.

Absorption of weakly acidic drugs occurs better within the acidic stomach environment while weak bases prefer the neutral to alkaline intestinal environment. Drug formulation practices base their strategies on pKa values for maintaining drugs in absorbable states at absorption sites.

4.3.6 Chemical and Physical Stability

A drug's stability level affects both its storage duration and its performance strength and security attributes. Drug stability determines how both chemically unstable drugs break down into harmful products and physically unstable formulations break down into various problems which alter drug release capabilities and availability.

Formulators execute stability improving measures through pH buffering and antioxidant addition and protective matrix encapsulation methods (such as liposomes) as well as refrigerator storage. A drug needs to maintain its stability within the gastrointestinal environment for proper drug integrity. until absorption occurs.

4.4 DISSOLUTION AND DRUG RELEASE TESTING

Drug development together with quality control depends heavily on the use of dissolution and drug release testing standards. Drug testing procedures determine the tijdframe and efficiency through which medications release from their dosage forms into solution while replicating gastrointestinal tract conditions [16]. The bloodstream accepts only dissolved drugs thus dissolution testing acts as an indicator to predict drug performance behavior in vivo. The following part examines the significance of dissolution tests containing method descriptions along with a review of regulatory standards.

4.4.1 Importance of Dissolution Testing

The procedure of dissolution testing functions as an alternative for bioavailability laboratory work particularly before a drug moves into advanced development stages. Screening formulations becomes possible through this method and researchers can identify the best release configuration. New drug products undergo essential tests for this purpose as well as maintaining consistent results between production batches and drug longevity. The determination of dissolution profiles enables the creation of in vitro-in vivo correlations (IVIVC) which predicts drug behavioral patterns within the body without requiring intensive human research [17]. The inability to dissolve drugs properly tends to companion bad absorption patterns which mostly affect hydrophobic pharmaceutical agents (BCS Class II and IV drugs). Formulation scientists can resolve drug release problems by making early identification of dissolution issues followed by adjusts to excipients and alterations of granulation methods or tablet coatings. The detection of issues stemming from polymorphic changes and aging effects together with manufacturing errors can be achieved through dissolution testing due to its ability to analyze product therapeutic outcomes.

4.4.2 Compendial Methods

The United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) and British Pharmacopoeia (BP) together implement compendial methods as standardized procedures that receive their approval. The prescribed testing equipment consists of USP Apparatus I (basket method) as well as USP Apparatus II (paddle method) to mimic conditions within the gastrointestinal tract[18].

During tests the drug product sits in a dissolution medium composed of water or buffer solutions at different pH levels while drug release amounts get measured through UV spectroscopy or high-performance liquid chromatography (HPLC). The regulator parameters

for dissolution tests comprise medium selection as well as agitation speed control along with temperature maintenance at 37 degrees Celsius to represent bodily conditions.

The compendial dissolution tests which serve as legal requirements find usage during regulatory submission procedures. The tests serve as the fundamental quality standard which the government uses for drug approval control and submission of changes post-approval. Regulatory agencies demand drug manufacturers to show consistent drug release patterns as part of Good Manufacturing Practices (GMP).

4.4.3 Alternative and Advanced Methods

The evaluation of controlled-release and delayed-release and multiparticulate formulations struggles to find proper assessment through compendial methods. The assessment of drug release requires alternative assessment methods or customized approaches in these cases.

The evaluation of poorly soluble or poorly permeable drugs needs pH-gradient methods as well as biphasic dissolution systems and flow-through cell apparatus (USP Apparatus IV) to reflect real gastrointestinal conditions. The methods generate results with enhanced discrimination which correspond to actual gastrointestinal conditions involving pH variations and enzymatic activities and motility patterns [19]. Dissolution imaging along with in situ UV fiber-optic monitoring and automated sampling systems provide researchers real-time drug release profiling involving precise results. These research methods provide essential value for formulating next steps that precede clinical trials.

4.4.4 Regulatory Considerations and Compliance

The approval bodies consider dissolution testing as an essential quality control procedure. Bioequivalence testing for generic drugs and product reformulation approval as well as new manufacturing plant and batch quantity authorization utilize this method. Enhancements to pharmaceutical products need regulatory approval that requires proof the new formulation matches dissolution profiles of the present formulation[20].

The FDA together with the EMA and ICH offer specific standards for creating dissolution specification requirements. The dissolution method requires researchers to choose specific test parameters linked to discrimination as well as to select media and equipment methods then set appropriate acceptance parameters including Q value. A determination of whether in vivo bioequivalence studies require waivers comes from studying dissolution profiles under the Biopharmaceutics Classification System (BCS).

BIBLIOGRAPHY

1. Hafeez, M. N., Celia, C., & Petrikaite, V. (2021). Challenges towards targeted drug delivery in cancer nanomedicines. *Processes*, *9*(9), 1527.
2. Haider, M. S., Ahmad, T., Groll, J., Scherf-Clavel, O., Kroiss, M., & Luxenhofer, R. (2021). The challenging pharmacokinetics of mitotane: an old drug in need of new packaging. *European Journal of Drug Metabolism and Pharmacokinetics*, *46*(5), 575-593.
3. Halder, S., Tabata, A., Seto, Y., Sato, H., & Onoue, S. (2018). Amorphous solid dispersions of carvedilol along with pH-modifiers improved pharmacokinetic properties under hypochlorhydoria. *Biopharmaceutics & Drug Disposition*, *39*(4), 232-242.
4. Han, D. G., Cha, E., Joo, J., Hwang, J. S., Kim, S., Park, T., ... & Yoon, I. S. (2021). Investigation of the factors responsible for the poor oral bioavailability of acacetin in rats: physicochemical and biopharmaceutical aspects. *Pharmaceutics*, *13*(2), 175.
5. He, S., Cheng, Z., & Xie, F. (2023). Population pharmacokinetics and dosing optimization of gentamicin in critically ill patients undergoing continuous renal replacement therapy. *Drug design, development and therapy*, 13-22.
6. He, W., Xing, X., Wang, X., Wu, D., Wu, W., Guo, J., & Mitragotri, S. (2020). Nanocarrier-mediated cytosolic delivery of biopharmaceuticals. *Advanced functional materials*, *30*(37), 1910566.
7. Hedrich, W. D., Fandy, T. E., Ashour, H. M., Wang, H., & Hassan, H. E. (2018). Antibody–drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. *Clinical pharmacokinetics*, *57*, 687-703.
8. Henriques, P., Bicker, J., Carona, A., Miranda, M., Vitorino, C., Doktorovová, S., & Fortuna, A. (2023). Amorphous nasal powder advanced performance: in vitro/ex vivo studies and correlation with in vivo pharmacokinetics. *Journal of Pharmaceutical Investigation*, *53*(5), 723-742.
9. Hofsäss, M. A., & Dressman, J. (2020). Evaluation of differences in dosage form performance of generics using BCS-based biowaiver specifications and

biopharmaceutical modeling–case examples amoxicillin and doxycycline. *Journal of pharmaceutical sciences*, *109*(8), 2437-2453.

10. Hsu, J. C., Wu, M., Kim, C., Vora, B., Lien, Y. T., Jindal, A., ... & Wu, B. (2024). Applications of advanced natural language processing for clinical pharmacology. *Clinical Pharmacology & Therapeutics*, *115*(4), 786-794.
11. Hu, X., Zhang, J., Liu, R., Gao, S., Qing, Y., Yi, S., ... & Wang, J. (2021). Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
12. Hughes, G. J., Lee, R., & Sideras, V. (2018). Design and delivery of clinical pharmacokinetics in colleges and schools of pharmacy. American Journal of Pharmaceutical Education, 82(9), 6430.
13. Hwang, M., Chia, Y. L., Zheng, Y., Chen, C. C. K., He, J., Song, X., ... & Even, C. (2023). Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance. *British journal of clinical pharmacology*, *89*(5), 1601-1616.
14. Ibrahim, Y. H.-E. Y., Regdon, G., Hamedelniel, E. I., & Sovány, T. (2020). Review of recently used techniques and materials to improve the efficiency of orally administered proteins/peptides. *DARU Journal of Pharmaceutical Sciences, 28*, 403–416.
15. Islam, F., Khadija, J. F., Islam, M. R., Shohag, S., Mitra, S., Alghamdi, S., ... & Emran, T. B. (2022). Investigating polyphenol nanoformulations for therapeutic targets against diabetes mellitus. *Evidence-Based Complementary and Alternative Medicine*, *2022*(1), 5649156.
16. Jain, A., Sharma, T., Kumar, R., Katare, O. P., & Singh, B. (2022). Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC. *Drug delivery and translational research*, *12*(5), 1136-1160.
17. Jaiswal, S., Ahmed, T., Kollipara, S., Bhargava, M., & Chachad, S. (2021). Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets. *Drug Development and Industrial Pharmacy*, *47*(5), 778-789.

10.5281/zenedo.15960797

18. Jakubowska, E., Davin, S., Dumicic, A., Garbacz, G., Juppo, A., Michniak-Kohn, B., ... & Lulek, J. (2020). ORBIS (Open Research Biopharmaceutical Internships Support)–building bridges between academia and pharmaceutical industry to improve drug development. *Journal of Medical Science*, *89*(1), e419-e419.

19. Jiang, H., Xing, Z., Wang, Y., Zhang, Z., Kumah Mintah, B., Dabbour, M., Li, Y., He, R., Huang, L., & Ma, H. (2020). Preparation of allicin-whey protein isolate conjugates: Allicin extraction by water, conjugates' ultrasound-assisted binding and its stability, solubility and emulsibility analysis. Ultrasonics Sonochemistry, 63, 104981.

20. Johnson, M. L., Wang, J. S., Falchook, G., Greenlees, C., Jones, S., Strickland, D., ... & Burris III, H. (2023). Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours. *British Journal of Cancer*, *128*(10), 1906-1915.